• DCPS Identified as m7G-Related Biomarker in Diabetic Foot Ul

  2026-06-04

  This study uncovers the decapping scavenger enzyme (DCPS) as a novel N7-methylguanosine (m7G)-related biomarker influencing epithelial cell function in diabetic foot ulcers (DFUs). Utilizing transcriptomics, quantitative assays, and functional cell biology, the research demonstrates DCPS's regulatory role in cell proliferation, migration, and wound healing, suggesting new avenues for biomarker-driven management of chronic nonhealing wounds.

• 5-Methyl-CTP: Optimizing Modified mRNA Synthesis for Durable

  2026-06-03

  Explore how 5-Methyl-CTP enhances mRNA synthesis with improved stability and translation efficiency. This article uniquely details practical assay decisions, integration strategies, and the impact of recent animal vaccine breakthroughs.

• Neutrophil Extracellular Traps in CML: Effects of Tyrosine K

  2026-06-03

  This study demonstrates that neutrophil extracellular trap (NET) formation is significantly increased in chronic myeloid leukemia (CML) and is differentially modulated by various tyrosine kinase inhibitors (TKIs). The findings offer new mechanistic insight into how TKIs may contribute to vascular toxicity in CML, highlighting implications for both disease pathogenesis and therapy selection.

• Screening MMV Compounds for Potent Activity Against MDR Path

  2026-06-02

  This study systematically evaluated MMV Pandemic Response Box compounds for inhibitory activity against multidrug-resistant (MDR) clinical bacterial and fungal isolates. Notably, several antifungal agents, including Oteseconazole (VT-1161), demonstrated strong growth inhibition of Candida species, highlighting promising candidates for overcoming antifungal resistance.

• Berberine Hydrochloride Induces Tuft Cells to Counter Bone L

  2026-06-02

  This study reveals that berberine hydrochloride protects against estrogen deficiency-induced bone loss by promoting the expansion of intestinal tuft cells and restoring gut-bone immune balance. The findings highlight a novel gut-mediated osteoprotective mechanism with implications for postmenopausal osteoporosis research.

• Tomivosertib: Selective MNK1/2 Inhibition in Cancer Research

  2026-06-01

  Discover how Tomivosertib, a potent MNK1 inhibitor, advances cancer research through targeted modulation of the MNK-eIF4E signaling pathway. This in-depth guide explores mechanisms, protocol parameters, and translational insights unique to Tomivosertib.

• MK 0893: Potent Glucagon Receptor Antagonist for Diabetes Re

  2026-06-01

  MK 0893 is a selective, reversible glucagon receptor antagonist with nanomolar potency that blocks GCGR signaling by binding to an extra-helical allosteric site. This molecule enables precise inhibition of cAMP production and glucose excursion reduction in preclinical models, supporting advanced type 2 diabetes research.

• Technical Guidance for Neuromedin S (rat) in GPCR Research

  2026-05-31

  Neuromedin S (rat) provides a chemically defined, endogenous peptide agonist for precise activation of neuromedin U receptor signaling in controlled laboratory assays. It is intended for research applications such as GPCR/G protein pathway analysis, particularly in studies of energy homeostasis and stress response. This reagent is not suitable for diagnostic, therapeutic, or clinical use.

• Apicidin Disrupts Oocyte Maturation via Epigenetic Mechanism

  2026-05-30

  This study demonstrates that Apicidin, a natural histone deacetylase inhibitor and emerging mycotoxin, impairs oocyte quality by disrupting the meiotic apparatus and altering histone acetylation patterns. The findings highlight new epigenetic toxicity pathways relevant for reproductive biology and food safety risk assessment.

• Fenipentol (1-Phenylpentan-1-ol): Applied Workflows in GI Re

  2026-05-29

  Fenipentol, a bioactive small molecule from Ligusticum chuanxiong, enables advanced gastrointestinal and hepatic secretion studies through its unique choleretic and estrogen receptor-modulating properties. This article offers workflow-driven protocols, troubleshooting strategies, and actionable insights for maximizing reproducibility and sensitivity in experimental setups.

• Phosphatase Inhibitor Cocktail (2 Tubes, 100X): Protocol Gui

  2026-05-29

  The Phosphatase Inhibitor Cocktail (2 Tubes, 100X) preserves protein phosphorylation by inhibiting a broad spectrum of endogenous phosphatases during sample preparation. It is recommended for workflows such as immunoblotting, kinase assays, and mass spectrometry where maintaining phosphorylation states is critical. This product should not be used for diagnostic or therapeutic applications.

• Light-Inducible RNA-Releasing Proteins for Gene Therapy Cont

  2026-05-28

  A recent study introduces a rationally designed light-inducible RNA-releasing protein (LIRP) that enables precise, reversible translational control of therapeutic gene expression in vivo. This optogenetic approach provides a new safety paradigm for gene therapies requiring temporal regulation, with demonstrated efficacy in liver, retinal, and metabolic disease models.

• Sulfamonomethoxine: Applied Protocols in Veterinary and Aqua

  2026-05-28

  Sulfamonomethoxine (SMM) stands apart for its versatility as a veterinary and aquaculture antibiotic, with unique environmental degradation pathways and actionable protocols for toxicity testing and biotransformation research. This article distills advanced insights and troubleshooting strategies, empowering researchers to maximize SMM's utility while navigating evolving regulatory and ecological demands.

• Tioconazole in Antifungal Research: Applied Workflows & Opti

  2026-05-27

  Tioconazole stands out as a high-purity, reliable antifungal medication for in vitro and in vivo research, thanks to its robust inhibition of the ergosterol biosynthesis pathway. This article translates advanced mechanistic insights and recent reference findings into actionable protocols, troubleshooting strategies, and comparative advantages for antifungal drug development.

• Primidone (Mysoline): Protocols and Innovations in ALS & TRP

  2026-05-27

  Primidone (Mysoline) has emerged as a powerful dual inhibitor of RIPK1 and TRPM3, driving advances in neurodegenerative and neurodevelopmental disease modeling. This article delivers evidence-based protocols, practical troubleshooting, and translational insights for deploying Primidone in bench workflows—empowering researchers with actionable, reproducible outcomes.

453 records 16/31 page Previous Next First page 上5页 1617181920 下5页 Last page